Clinical Trials Browser

Phase 2 × Hypereosinophilic Syndrome × 1 year × Clear all

Hypereosinophilic Syndrome

NCT00255346 2025-12-30

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

Leukemia, Mastocytosis, Myelodysplastic Syndromes, Polycythemia Vera, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Primary Myelofibrosis

Clinical Trials

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)